MAFLD cases demonstrated significantly greater metabolic severity, evidenced by elevated BMI (31.49 ± 6.63 vs 21.70 ± 4.18 kg/m2), worsened insulin resistance (HOMA-IR 5.44 ± 3.59 vs 2.48 ± 1.44), and more pronounced hepatic injury markers (ALT 21.85 ± 13.04 vs 14.36 ± 7.40 U/L; all p < 0.001). The gene discussed is GPT; the disease is Insulin resistance.